Furthermore, Park et al. suggested that an OGT inhibitor reduces lipid accumulation induced by high glucose, while blocking OGA enhances lipid accumulation in HepG2 cells and the liver of zebrafish larvae, supporting the promising role of enzymes involved in O-GlcNAcylation and the HBP as targets for NAFLD therapy [79]. Here, OGT is linked to metabolic dysfunction-associated steatotic liver disease.